CMB International Leads $100M Series B Round Into US Biopharmaceutical Firm

U.S. biopharmaceutical company Apollomics, Inc., has raised US$100 million in a series B financing round, led by CMB International (CMBI), a subsidiary of China Merchants Bank. The round was also participated in by existing series A round investor, OrbiMed Asia, according to an announcement today. 

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets